adcendo
Manufacturing · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Copenhagen, Capital Region, DenmarkWebsite
www.adcendo.dkRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About adcendo
Adcendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. The company focuses on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is adcendo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if adcendo had a recent Job posting/layoffs
Funding: Get notified immidiatlly once adcendo has new funding data
Product Launch: Get notified when adcendo launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on adcendo recently announced quarterly report
Check out if adcendo is spiking on competitors!
Check if adcendo has recently received funding, and reach out quickly before it becomes old news!
adcendo, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at adcendo
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
adcendo is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
adcendo is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about adcendo.
adcendo financials insights
Gather financial insights about adcendo, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$62M
adcendo Tech Stack
A closer look at the technologies used by adcendo
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
New Hire
Executive Move
Lateral Move
Executive Move
adcendo News & Media
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development
BEIJING--(BUSINESS WIRE)-- #ADC--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that Adcendo ApS ("Adcendo"), a biotech company focused on the development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need, has exercised its option under a research, option and license agreement to utilize Biocytogen’s fully human antiDuality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement
Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its first-in-class ADC pipeline PRINCETON, N.J., SHANGHAI and SUZHOU, China, Nov. 26, 2024 /PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate therapeutics today announced the expansion of its ongoing collaboration with Adcendo ApS ("Adcendo"), a biotech company focused on the development of firDuality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement
Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its first-in-class ADC pipeline PRINCETON, N.J., SHANGHAI and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage biotech company focusing on the discovery...Adcendo Raises €31M; Extends Series A Round to €82M
Adcendo ApS, a Copenhagen, Denmark-based biotech company focused on the development of antibody-drug conjugates (ADCs) for the treatment of cancers, raised €31M in Series A extension funding. The round, which brought the total amount to $82M, was led by Pontifax Venture Capital, and existing investors Novo Holdings and Ysios Capital. Current investors RA Capital Management, […] The post Adcendo Raises €31M; Extends Series A Round to €82M appeared first on FinSMEs.
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding adcendo
Sign Up For FreeTo access detailed company insights
Adcendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. The company focuses on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.... Read More
